Short-term and long-term changes in immune status in BMF mice by RUX therapy. (A) T-cell phenotype of BM-infiltrated CD4⁺ and CD8⁺ T cells. BMF CByB6F1 mice treated with RUX were euthanized at 2 weeks (RUX-W2, n = 10, short-term) and 8 weeks (RUX-W8, n = 10, long-term) following LN cell infusion, along with TBI mice at 8 weeks (TBI, n = 5) as controls. BMF mice without treatment (BMF, n = 10) were euthanized at 2 weeks because almost all mice would die within 3 weeks post LN cell infusion if untreated. BM cells and plasma samples were collected and stored at −80°C until analysis. T-cell activation marker CD25 and immune checkpoint and T-cell exhaustion marker PD-1 are shown in representative flow cytometry plots and histograms. (B) Cytokine profiles of RUX-treated mice. Inflammatory cytokines including IFN-γ, TNF-α, IL-5, IL-1a, CCL2, FasL, CCL5, and IL-10 in plasma samples from different experiments were measured by Luminex simultaneously. TBI (n = 5), BMF (W2, n = 17), RUX-W2 (n = 25), and RUX-W8 (n = 10) mice, shown as individual observations. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001.